Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

Fishing for Further Reductions in Residual Cardiovascular Risk

03/31/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews two of the latest trials evaluating the controversial topic of fish oils products, and attempts to get the bottom of this murky pond of conflicted evidence.

Dr Jennings reviews two of the...

03/31/2021

Pharmacy Learning Network

Talking Therapeutics

Straight Talk on COVID-19 Farses

01/19/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's issue of Talking Therapeutics, Dr Jennings discusses COVID-19 misinformation, how it could impact patient health and industry costs, and how pharmacists can combat it.

In this week's issue of Talking...

01/19/2022

Pharmacy Learning Network

Talking Therapeutics

Fighting Endocarditis One Antibiotic at a Time

09/22/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews guideline recommendations and new research into the use of antibiotics in patients who are about to undergo invasive dental procedures.

Dr Jennings reviews guideline...

09/22/2022

Pharmacy Learning Network

Talking Therapeutics

Small Targets Equal Big Gains for Treating Hypertension

07/26/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings walks through a study on zilebesiran, an investigational small interfering RNA therapy, for the treatment of patients with hypertension.

Dr Jennings walks through a...

07/26/2023

Pharmacy Learning Network

Talking Therapeutics

Finding Novel Therapies for COVID-19

01/19/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In light of new research and the ongoing evolution of the SARS-CoV-2 virus, Dr Jennings reviews efficacy data on 2 non-antiviral drugs for the treatment of patients with COVID-19.

In light of new research and the...

01/19/2023

Pharmacy Learning Network

Talking Therapeutics

Take It Slow or Move to the Rhythm?

08/18/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s edition of Talking Therapeutics, Dr Jennings explores the latest clinical trial data comparing rhythm-control strategy vs usual care for the treatment of patients with atrial fibrillation.

In this week’s edition of...

08/18/2021

Pharmacy Learning Network

Talking Therapeutics

ACC.22 Update Part 2: Influenza Vaccines, EHR Alerts, PCSK9 Inhibitors

04/14/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings returns with another ACC.22 round up, including new research on influenza vaccines, electronic health record alerts for providers, and more.

Dr Jennings returns with another...

04/14/2022

Pharmacy Learning Network

Talking Therapeutics

AHA Scientific Sessions 2022 Update, Part 2: The Diuretic Wars

11/17/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the second part of his coverage of AHA Scientific Sessions 2022, Dr Jennings shares 2 randomized trials designed to compare diuretics for the treatment of hypertension and heart failure.

In the second part of his...

11/17/2022

Pharmacy Learning Network

Talking Therapeutics

Time to Discontinue Levothyroxine for Heart Organ Donors

12/04/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s installment of Talking Therapeutics, Dr Jennings evaluates a recent randomized trial to address how hormone deficiency can lead to myocardial energy depletion and subsequent decline in cardiac function in donor recipients.

In this week’s installment of...

12/04/2023

Pharmacy Learning Network

Talking Therapeutics

COVID-19 Catchup: New Pills, Steroid Dosing

11/10/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the wake of recent research and news, Dr Jennings discusses the efficacy and safety of two COVID-19 pills, as well as corticosteroid dosing for patients with hypoxemia.

In the wake of recent research...

11/10/2021

Pharmacy Learning Network